OBJECTIVES The aim of this study was to determine whether coronary artery calcium (CAC) progression was associated with coronary plaque progression on coronary computed tomographic angiography.
A therosclerotic plaque progression is a complex process that is associated with multiple factors, such as wall shear stress, plaque structural stress, inflammation, endothelial dysfunction, neovascularization, and alterations in mineral metabolism (1) (2) (3) (4) (5) (6) . Coronary plaque progression might have an added value in risk stratification as risk stratification of plaques based on the morphological characteristics at a single region of the plaque, usually the minimal lumen diameter, may be misleading (7) .
Several invasive modalities, such as intravascular ultrasound (IVUS) and optical coherence tomography, allow for the visualization, categorization, and quantification of coronary plaque and are used for the assessment of plaque progression. Until recently, visual assessment and visual quantification of coronary plaque was only possible during cardiac (coronary) computed tomography angiography (CTA).
New methods for semiquantitative plaque assessment have emerged with good correlation to IVUS, allowing a more precise quantification of coronary plaque (8) , suggesting that it potentially can be an alternative tool to identify coronary atherosclerosis and its progression.
Coronary artery calcium (CAC) visualized on noncontrast computed tomography (CT) is a robust marker of atherosclerosis because CAC reflects overall coronary atherosclerosis burden including calcified and noncalcified plaques (9) . Several studies demonstrated a strong association of CAC progression with the risk of cardiovascular disease (CVD) and cardiovascular mortality (10) (11) (12) . However, the natural history of coronary atherosclerosis has not been well described to date, and the clinical and pathological understanding of the association between CAC progression and other coronary plaques such as noncalcified plaque progression remains unclear.
However, reports of CAC progression associated with statin use has cast doubt on the underlying atherosclerotic process occurring as CAC progresses (stabilization versus progression).
We aimed to evaluate the association of CAC progression with change in atherosclerotic plaque volume and its subtypes using quantitative plaque analysis software.
METHODS
STUDY POPULATION. Two hundred eleven consecutive patients, who were referred to our clinic for evaluation and had serial cardiac CT (coronary CTA) scans performed, were included in the study. Patients with nondiagnostic baseline or follow-up scans, previous coronary artery bypass grafts, coronary revascularization between baseline and follow-up, or <1-year interval between baseline and follow-up scans were excluded from the study. Coronary artery disease (CAD) risk factors were defined as previously reported (13 (14) . Semiautomated plaque volume quantification was performed using methodology described previously (8, 16, 17) . Vessel and plaque volumes at baseline and follow-up were measured in segments with sufficient image quality and $1.5 mm in lumen diameter. Segments with stents were excluded. STATISTICAL ANALYSIS. Kruskal-Wallis test was used for comparisons between several groups of nonparametric continuous variables ( Figure 1) . The Mann-Whitney U test was used for the comparison between nonparametric data ( Figure 2 
RESULTS
Baseline patient characteristics are described in progression was associated with a significant linear increase in all types of coronary plaque ( Figure 1 ).
In multivariate regression analysis, annual CAC progression was significantly associated with total plaque volume, NCP, fibrous PV, and densely calcified PV progression ( Table 3) . CAC progression was not associated with low-attenuation plaque or fibrousfatty plaque progression. Figure 3 ). An example of plaque progression in mid LAD is provided in Figure 4 .
DISCUSSION
In the current study, by using semiautomated plaque quantification software we demonstrated that CAC progression was associated not only with calcified plaque progression, as expected, but also with NCP, namely fibrous plaque, progression. To our knowledge, our study is the first to evaluate the association between progression of CAC and different coronary plaque subtypes, although several studies addressed the association of CAC progression with cardiovascular outcomes (18) (19) (20) .
Our current findings regarding the association of progression between CAC scores and noncalcified plaque volumes provide support to the concept that CAC progression is associated with more CVD events (18) (19) (20) . Calcified plaque has been considered to be a 22.42 p = 0.07 p = 0.12 p = 0.07 p = 0.01 p = 0.08 p = 0.01 p = 0.85 17.14 7.43 p = 0.64 p = 0.41 p = 0.11 p = 0.14 p = 0.69 p = 0.09 p = 0.71 15.24 7.14 p = 0.004 p = 0.06 p = 0.68 p = 0.004 p = 0.22 p = 0.005 p = 0.87 CAC Change Is Associated With Coronary Plaque Volume Progression -2 0 1 7 : --process of atherosclerosis is highly dynamic rather than linear and depends on the local pathobiological stimuli for plaque progression, such as local remodeling response (7, 21, 22) , and progression in calcified and noncalcified plaques may coexist during the process. In this regard, individuals with CAC progression may also experience progression in total plaque burden including both calcified and noncalcified plaques that is observed in the current study, resulting in a higher incidence of CVD events.
Statins

Overall, this may be more suitable to evaluate CVD risk at a per-patient basis.
In the current study, despite a significant association between CAC progression and all types of plaque in univariate analysis, this association was no longer statistically significant for low-attenuation and fibrous-fatty plaque subtypes in multivariate analysis and did not correlate with absolute CAC progression.
These findings were of interest as multiple observational studies demonstrated that lipid-rich or vulnerable plaques as well as CAC progression are associated with increased risk of cardiovascular events. However, the relationship of risk in acute coronary syndrome between per-lesion and perpatient bases is complex and still an ongoing debate (23) . Progression in CAC and lipid-rich plaques may not always parallel, as there are many potential risk markers of CAD such as plaque burden, vulnerable plaque features, plaque activity, stenosis degree, and ischemia, all of which are associated with increased risk for CVD events but not always coexist (24) . In this regard, despite showing a similar positive trend, overall CAC progression may not always correlate well with progression in lipid-rich plaque associated with acute coronary syndrome that is described in the current study. Also, factors such as noncalcified plaque burden or traditional clinical risk factors other than CAC progression are associated with lipid-rich plaque progression. In a study of 142 matched subjects with and without diabetes, overall noncalcified plaque burden, but not baseline CAC score, was associated with fibrous-fatty and low-attenuation plaque progression (17) . A serial IVUS and nearinfrared spectroscopy study in 66 patients revealed that lipid-rich plaque burden was significantly associated with plaque burden, diabetes, and prior myocardial infarction, with plaque burden as the best predictor of the extent of lipid-rich plaques (25) .
These plaque subtypes are more likely to convert from more pathogenetically unstable noncalcified plaque, rather than more pathogenetically stable plaque, such as fibrous or calcified plaque (26) .
Therefore, noncalcified plaque burden may be more closely associated with fibrous-fatty and lowattenuation plaque progression.
In a subanalysis for assessing the relationship be- by the effect of statins on the composition of coronary plaque, described by other studies (29) (30) (31) . Our data support both the concept that statins inhibit noncalcified plaque progression and the recommendation Table 2 . 
CAC progression and plaque volume progression
are also associated with moderate to advanced chronic kidney disease (4). We did not have data in patients with renal failure, as only patients with normal or close to normal renal function underwent coronary CTA.
Although our study has clearly described the clinical impact on the association between CAC 
